
Schizophrenia and bipolar disorder are associated with a high burden of preventable physical disease, the primary driver of a ~12–15 year reduction in life expectancy. Existing treatments are largely symptomatic and contribute to this burden through adverse side effects.

We exist to unite emerging neurometabolic science, psychosocial innovation and biosensing technologies into a single dynamic biomarker discovery platform. As our platform scales, we transform how episodic neuropsychiatric diagnoses are understood, measured, and treated as brain-body illnesses.

We envision an entirely new future of state-targeted, disease-modifying therapeutics. This paradigm shift enables diagnostic labels of 'schizophrenia' and 'bipolar disorder' to be re-classified as neurometabolic illnesses, capable of achieving durable remission while safeguarding whole-body health.
Wisdom in action is the practice of uniting intuition and discernment to bridge differing perspectives for our collective goal of driving change. It means we face what's uncomfortable and integrate what's opposing, to transform complexity into clarity.
Sovereignty is the discipline of providing power to people. This looks like designing solutions which break cycles of systemic dependency, toward achieving lasting agency with compassionate safeguards.
Audacious science is the courage to imagine and create beyond convention to deliver a future the world has not yet seen. Our work begins where current standard of care ends: with critical discussion, novel science, non-consensus inquiry and technologies designed to reveal the full scope of our vision.
Intellectual honesty is our discipline of confronting reality as it is and adapting to evidence wherever it leads. It calls for self-awareness to question our own assumptions, admit and learn from our errors to share those lessons openly across the company. Through this, we create the freedom to take intelligent risks and learn fast.


Explore our collection of 200+ Premium Webflow Templates